Sporadic CDKN2 (MTS1/p16\textsuperscript{ink4}) gene alterations in human ovarian tumours

M Schuyer\textsuperscript{1}, IL van Staveren\textsuperscript{1}, JGM Klijn\textsuperscript{1}, MEL v.d. Burg\textsuperscript{1}, G Stoter\textsuperscript{1}, SC Henzen-Logmans\textsuperscript{2}, JA Foekens\textsuperscript{1} and EMJJ Berns\textsuperscript{1}

\textsuperscript{1}Division of Endocrine Oncology (Department of Medical Oncology) and \textsuperscript{2}Department of Pathology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

Summary The cell cycle regulatory proteins p16 and p21 cause cell cycle arrest at the G1 checkpoint by inhibiting activity of cyclin D–CDK4 complexes. The TP53 gene, regulating the p21 protein, is mutated at high frequency in ovarian cancer. The CDKN2 gene, encoding the p16 protein, has been mapped to chromosome 9p21 and encompasses three exons. To establish the frequency of CDKN2 gene abnormalities in ovarian tumour specimens, we have studied this gene in five ovarian cancer cell lines and in 32 primary and five metastatic ovarian adenocarcinomas. Using polymerase chain reaction–single strand conformation polymorphism (PCR–SSCP) and sequencing techniques both exon 1 and 2 of the CDKN2 gene, encompassing 97\% of the coding sequence, were analysed. In addition, the TP53 gene was studied for the presence of mutations. The cell line HOC-7 showed a 16 bp deletion in exon 1C of the CDKN2 gene, resulting in a stop codon, whereas in cell line SK-OV-3 this gene was found to be homozygously deleted. Nine primary tumour specimens showed a migration shift on SSCP. Sequencing revealed a common polymorphism (Ala148Thr) in seven of these ovarian tumour specimens. The two other tumour samples were found to contain silent mutations, one at codon 23 (GCT→GCA) and the other at codon 67 (GGC→GGA). Mutations in the TP53 gene were observed in 46\% of the ovarian tumour specimens. We conclude that CDKN2 gene alterations are rare events in human ovarian cancer. The low prevalence of these alterations do not allow for analysis of an association of this gene with prognosis.

Keywords: CDKN2; MTS1; p16\textsuperscript{ink4}; ovarian cancer; mutation; TP53

Cyclins, cyclin-dependent kinases (CDKs) and cyclin-dependent kinase inhibitors (CKIs) play a key role in cell cycle control. To achieve an orderly progression through the cell cycle, different cyclin–CDK complexes need to be activated and deactivated at appropriate times. Cyclin D–CDK4 is one of the complexes that promotes cell passage through the G1 phase of the cell cycle. It increases the phosphorylation state of the retinoblastoma protein which then releases transcription factors (e.g. E2F) essential for progression into the S-phase (reviewed by Sherr, 1993; Hartwell and Kastan, 1994; Hunter and pines, 1994).

Changes in the amount or composition of CDKs or their inhibitors may lead to loss of cell cycle control and thus to uncontrolled cell growth.

One of the inhibitors of cyclin D–CDK4 as well as of other cyclin–CDK complexes throughout the whole cell cycle is the p21 protein, encoded by the WAF1 (CIP1/SDI1) gene (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993). Upon genotoxic damage, expression of p21 is induced through the transcriptional activation by TP53\textsuperscript{mut} (El-Deiry et al., 1994). The TP53 gene is located on chromosome 17p13.1 and mutation of this gene is the most common genetic abnormality yet found in human cancers. The prevalence of TP53 mutations varies among tumour types with roughly 44\% of ovarian tumours being mutated (reviewed by Greenblatt et al., 1994).

Another negative regulator of cyclin D–CDK4/6 activity is the p16 protein, encoded by the CDKN2 (MTS1/p16\textsuperscript{ink4}; CDK4I) gene (Serrano et al., 1993; Nobori et al., 1994). The CDKN2 gene, which has been mapped to chromosome 9p21, was found to be deleted or mutated in a wide variety of tumour cell lines, including nearly 30\% of ovarian cancer cell lines (Kamb et al., 1994). Interestingly, loss of heterozygosity (LOH) at 9p has been reported in 31\% (49 out of 157) of human epithelial ovarian tumours (reviewed by Shelling et al., 1995).

To determine whether alterations of the CDKN2 gene are involved in ovarian carcinogenesis, we have studied this gene in 32 primary and five metastatic human epithelial ovarian tumour specimens and in an additional five ovarian cancer cell lines. To this end, exons 1 and 2, constituting 97\% of the coding sequence, were examined using PCR–SSCP and sequencing techniques. Our results suggest that alterations of the CDKN2 gene play no major role in the initiation or progression of ovarian cancer.

Materials and methods

Cell lines

The human ovarian cancer cell lines used in this study were SK-OV-3 (HTB-77), SK-OV-6, 2780, 2774, HOC-7 (a gift from Dr. Günther D. Henrichsler, Innsbruck, Austria). The SK-OV-3 and HOC-7 cell lines originated from ascites, whereas the other cell lines were derived from (aden)o)carcinomas (ATCC).

Tumour samples

Thirty-two primary and five metastatic ovarian adenocarcinomas were included in this study. One patient had bilateral adenocarcinoma of the same histological type. A sample of both locations was investigated. The mean age as well as the median age of the patients with ovarian tumours was 56 years (range, 26–85 years). Following the WHO (1979) classification the primary and metastatic carcinomas were subtyped into serous (n=14 primary, n=5 metastatic), mucinous (n=4), endometroid (n=7), clear cell (n=2), mixed (n=3), poorly differentiated (n=1) and unknown (n=1). To estimate the percentage of tumour cells, frozen sections were made from a representative part of each tumour and stained with haematoxylin and eosin. The

Correspondence: EMJJ Berns, Division of Endocrine Oncology, Dr Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands

Received 16 November 1995; revised 19 April 1996; accepted 24 April 1996
percentages of tumour cells in the primary tumour specimens were: below 25% \((n=8)\), between 25% and 50% \((n=3)\), between 50% and 75% \((n=8)\) and above 75% \((n=12)\). With respect to the metastatic tumour specimens, the percentages of tumour cells were: between 50% and 75% \((n=3)\) and above 75% \((n=2)\). In general, 68% of these tumours contained over 50% of tumour cells.

**DNA extraction, polymerase chain reaction (PCR), single strand conformation polymorphism (SSCP) analysis and sequence analysis**

Tumour specimens were stored in liquid nitrogen. Genomic DNA was extracted from frozen tumour tissues or cell lines according to standard procedures (Sambrook et al., 1989).

Exons 1 (150 bp) and 2 (307 bp) of the CDKN2 gene (Okamoto et al., 1994) as well as exons 5, 6, 7 and 8 of the TP53 gene were studied by PCR–SSCP analysis (Orita et al., 1989). Locations and sequences of PCR–primers for exon 1 (Okamoto et al., 1994) and for exon 2 (Berns et al., 1995) of the CDKN2 gene are shown in Figure 1 and Table 1 respectively.

Briefly, exon 1 was amplified by PCR using intronic primer pairs (Okamoto et al., 1994) as shown in Table 1. Exon 2 was amplified using primer pair M2-U/M2-D, generating a 522 bp fragment. To enhance specificity and to generate smaller fragments, two nested PCRs were carried out using primer pairs A1/A2 and B1/M2-D. About 200 ng genomic DNA was used for PCR. Amplification was performed in the presence of 10% dimethyl sulphoxide (DMSO) and \([\alpha^32P]dATP\) using a

![Primer locations](image)

**Figure 1** Top: Primer locations for amplification of exon 1 and exon 2 of the CDKN2 gene as described in the Materials and methods section. Bottom: Examples of PCR–SSCP analyses of CDKN2 fragments. (a) A migration shift in exon 1. (b and c) Migration shifts in exon 2. The corresponding sequence analyses are shown in Figure 2. The asterisks indicate the altered migration patterns. D, denatured; ND, not denatured.

| Table 1 | Primer sequences for amplification of exon 1 and exon 2 of the CDKN2 gene |
|---------|--------------------------------------------------------------------------|
| **Exon** | **Primer sequences** | **Cycling parameters** |
| 1       | M1-U: 5'-CCGAGAGGGGGGAGAGAGCAG-3' | 50 s 92°C, 30 s 60°C, 2 min 72°C, 30 cycles |
|         | M1-D: 5'-TCCCCCTTTTTTCGAGAATCG-3' |                     |
| 2       | M2-U: 5'-GAGAAGCTCAAGGAAGAAATTGG-3' | 50 s 92°C, 50 s 57°C, 2 min 72°C, 30 cycles |
|         | M2-D: 5'-TCTGAGCTTTGGAAAGCTCTCA-3' |                     |
|         | Nested primers |                     |
| A1: 5'-AGCTTCTTTTCGTCATGC-3' | 50 s 92°C, 50 s 57°C, 2 min 72°C, 20 cycles |
| A2: 5'-ACCACCGCGTTCCAGGAAG-3' |                     |
| B1: 5'-ACTCTCACCAGGACCCGTG-3' |                     |
| M2-D: 5'-TCTGAGCTTTGGAAAGCTCTCA-3' |                     |

1070

CDKN2 gene alterations in ovarian cancer
M Schuyer et al
DNA thermal cycler-480 (Perkin Elmer/Cetus, Norwalk, CT, USA). To improve specific annealing, a touchdown PCR procedure was used. Cycling parameters are listed in Table I. Genomic input DNA and PCR product ratios were compared on ethidium bromide-stained agarose gels (1.3%) following the first 30 cycles of PCR. The breast cancer cell lines, MCF7 and MDA-MB-231, which have a homozygous deletion of the CDKN2 gene (Berns et al., 1995), were taken as a control.

The exons 5, 6, 7, and 8 of the TP53 gene were amplified using commercially available primers (Clontech, Palo Alto, CA, USA). To obtain a false negative rate below 10%, products of less than 200 bp were generated (Hayashi and Yandell 1993). To this end, the TP53 PCR products were digested with HinfI (exon 5), HaeIII (exon 6) and BsrI (exon 8). Exon 1 of the CDKN2 gene was digested with BsrI and exon 2 (fragment B1/M2-D) was digested with KpnI. For SSCP analysis 32P-labelled PCR products were heat denatured and applied to a non-denaturing 8% polyacrylamide gel containing 10% (v/v) glycerol and electrophoresis was performed at 30 W for 6 h at room temperature. PCR products showing an altered electrophoretic mobility were analysed again and then subcloned into a TA cloning vector (PCRII; Invitrogen, San Diego, CA, USA). At least ten individual clones were pooled and sequenced by double-stranded sequencing (T7 sequencing kit, Pharmacia, Uppsala, Sweden) using a 6% denaturing polyacrylamide gel containing 8 M urea.

### Results

We have studied alterations in exons 1 and 2 of the CDKN2 gene in 32 primary and five metastatic ovarian adenocarcinomas and in five ovarian cancer cell lines using PCR–SSCP and sequencing techniques.

Two cell lines, SK-OV-3 and HOC-7, showed alterations in the CDKN2 gene. No PCR products for exon 1 and 2 could be generated using the cell line SK-OV-3, indicating that the CDKN2 gene is homozygously deleted in this cell line. The integrity of the DNA was confirmed by a successful amplification of TP53 (exons 5–8). The cell line HOC-7 was found to have a 16 bp deletion in exon 2 of the CDKN2 gene. This deletion removes nucleotides at positions 163–178, thereby placing the sequence in a different reading frame and introducing a stop codon 256 bp downstream from the deletion. In addition, this cell line also has a mutation (T→A) 36 bp downstream of this deletion.

Among the 32 primary tumours examined a total of nine (28%) altered migration patterns were detected (Figure 1 and Table II). Two mobility shifts correlated with silent mutations in exon 1 (codon 23:GGT→GGA) and exon 2 (codon 67:GTC→GTT; Figure 2). The remaining seven (22%) mobility shifts represented a common polymorphism (GCG→ACG; Figure 2), substituting a threonine for an alanine at codon 148. The metastatic tumour specimens, however, revealed no mobility shifts by SSCP.

With respect to TP53 gene alterations, 13 out of 32 (41%)

### Table II Genetic alterations of the CDKN2 and TP53 genes in primary and metastatic ovarian adenocarcinomas

| Sample | Histology  | Tumour cells (%) | TP53 alteration | CDKN2 alteration | Amino acid change |
|--------|------------|------------------|----------------|-----------------|------------------|
| Primary |            |                  |                |                 |                  |
| 591    | Serous     | ≤25              | Exon 6         | 6               | 67 GGC→GTT      | Gly→Gly         |
| 615    | Serous     | ≤25              | Exon 2         | 2               | 148 GCG→ACG     | Ala→Thr         |
| 602    | Serous     | ≤25              |                |                 |                  |
| 638    | Mucinous   | ≤25              | Exon 2         | 2               | 148 GCG→ACG     | Ala→Thr         |
| 580    | Mucinous   | ≤25              |                |                 |                  |
| 623    | Endometrioid| ≤25             | Exon 2         | 2               | 148 GCG→ACG     | Ala→Thr         |
| 624    | Mixed      | ≤25              |                |                 |                  |
| 604    | Unknown    | ≤25              |                |                 |                  |
| 582    | Serous     | 25–50            | Exon 2         | 2               | 148 GCG→ACG     | Ala→Thr         |
| 603    | Serous     | 25–50            |                |                 |                  |
| 657    | Mucinous   | 25–50            |                |                 |                  |
| 601    | Serous     | 50–75            |                |                 |                  |
| 616    | Serous     | 50–75            |                |                 |                  |
| 626    | Serous     | 50–75            |                |                 |                  |
| 585    | Serous     | 50–75            |                |                 |                  |
| 618    | Serous     | 50–75            |                |                 |                  |
| 459    | Poorly differentiated | 50–75 |                | 6               |                  |
| 545    | Mixed      | 50–75            |                |                 |                  |
| 649    | Mixed      | 50–75            |                |                 |                  |
| 553    | Serous     | ≥75              |                |                 |                  |
| 562    | Serous     | ≥75              |                |                 |                  |
| 621    | Serous     | ≥75              |                |                 |                  |
| 565    | Mucinous   | ≥75              |                |                 |                  |
| 620    | Endometrioid| ≥75            |                | 2               | 148 GCG→ACG     | Ala→Thr         |
| 622    | Endometrioid| ≥75            |                | 5               |                  |
| 564    | Endometrioid| ≥75            |                | 6               | 148 GCG→ACG     | Ala→Thr         |
| 605    | Endometrioid| ≥75            |                | 7               | 148 GCG→ACG     | Ala→Thr         |
| 595    | Endometrioid| ≥75            |                | 2               | 148 GCG→ACG     | Ala→Thr         |
| 612    | Endometrioid| ≥75            |                |                 |                  |
| 625    | Clear cell | ≥75              |                | 1               | 23 GGT→GGA      | Gly→Gly         |
| 586    | Clear cell | ≥75              |                |                 |                  |
| 596    | Serous     | Not determined   |                |                 |                  |
| Metastatic |        |                  |                |                 |                  |
| 583    | Serous     | 50–75            |                | 5               |                  |
| 617    | Serous     | 50–75            |                | 8               |                  |
| 540    | Serous     | 50–75            |                |                 |                  |
| 547    | Serous     | ≥75              |                | 7               |                  |
| 574    | Serous     | ≥75              |                | 5               |                  |
primary tumour specimens and four out of five (80%) metastatic tumour specimens showed altered migration patterns on SSCP. Of the seven tumours having a polymorphism in the CDKN2 gene three tumour specimens showed an alteration in the TP53 gene. DNA sequencing analysis showed that two mutations occurred in exon 7 (Arg248Trp and Arg248Leu), whereas the third mutation was found in exon 6 (Ile195Thr; Table II). Of the two tumours having a silent CDKN2 gene mutation, one also showed a mutation in exon 6 (Arg213stop) of the TP53 gene.

**Discussion**

To determine whether alterations of the CDKN2 gene may be critical in the formation of ovarian cancer, we have analysed primary and metastatic ovarian adenocarcinomas and ovarian cancer cell lines for the presence of CDKN2 gene alterations. One of the five cell lines tested, SK-OV-3, was found to be homozygously deleted for the CDKN2 gene, whereas another cell line, HOC-7, showed a partial deletion of 16 bp in exon 2, resulting in a frameshift and a premature stop codon. Okamoto et al. (1994) and Schultz et al. (1995) also found a homozygous deletion in the cell line SK-OV-3. Homozygous deletions have been reported in nearly 30% (two out of seven) of ovarian cancer cell lines (Kamb et al., 1994). Our solid ovarian tumour specimens, however, were not indicative of homozygous deletions. Among the 32 primary ovarian adenocarcinomas studied, only two silent mutations were found in one out of 14 serous and one out of two clear cell tumour specimens. The common polymorphism Ala148Thr, previously described as Ala140Thr by Cairns et al. (1994), was observed in seven ovarian adenocarcinomas (one out of 14 serous, two out of four mucinous, three out of seven endometroid and one out of one unknown. We observed no CDKN2 alterations in five metastatic tumour samples. Campbell et al. (1995) and Schultz et al. (1995) observed no mutations in 67 primary and five out of 40 ovarian tumours showing LOH on 9p respectively. In addition, the latter author reported homozygous deletions of the CDKN2 gene in 14% (16 out of 115) of ovarian neoplasms using comparative multiplex PCR. However, 50% of the tumours used in their study were common epithelial tumours, whereas the other 50% were of different histopathological subtype, mainly benign tumours.

The low prevalence of CDKN2 gene alterations observed by us may also be explained by technical difficulties associated with primary tumour studies. Data on analyses of mutations or other genetic abnormalities in tumours where the material studied contains less than 50% tumour cells should be interpreted with caution. For example, the presence of homozygous deletions in tumours may be masked by a considerable non-neoplastic cell content. Although in the present study the majority of the tumours contained over 50% of tumour cells, we were not able to observe major differences in signal intensities when comparing genomic input DNA and PCR product ratios (after 30 cycles). In addition, with respect to mutations concern may also exist. However, Table II shows that CDKN2 and TP53 gene mutations are equally prevalent in tumour samples with either a smaller or a higher percentage of tumour cells. A possible underestimation of mutations and/or deletions in tumour tissues could be excluded by dissecting tumour cells from surrounding normal tissue. Another explanation for the low prevalence of CDKN2 gene mutations may be the sensitivity of the SSCP technique. To reduce the false-negative rate below 10%, we digested the PCR products used in this study in order to generate fragments of less than 200 base pairs (Hayashi and Yandell, 1993). Moreover, a normal TP53 mutation spectrum was observed since, of all tumours studied, 46% showed a TP53 alteration as determined by SSCP. A recent review by Shelling et al. (1995) reported that 44% (46 out of 105) ovarian tumours showed TP53 mutations, measured by SSCP.

A low frequency of CDKN2 gene alteration in tumours and a higher frequency in cell lines has also been described in tumours of the breast (Xu et al., 1994; Berns et al., 1995), head and neck (Zhang et al., 1994; Lysiatt et al., 1995), lung, bladder, kidney, brain and colon (Cairns et al., 1994; Spruck et al., 1994). In contrast, homozygous deletions and/or mutations occur more often in mesotheliomas (Cheng et al., 1994), melanomas (Hussussian et al., 1994), non-small-cell lung carcinomas (Hayashi et al., 1994), glioblastomas (Schmidt et al., 1994) and several other tumours (Mori et al., 1994; Caldas et al., 1994).

This study does not rule out a putative role of methylation of the CDKN2 gene in ovarian cancer. De novo methylation of the 5'CpG island of CDKN2 is a frequent abnormality in non-small-cell lung cancer, gliomas, head and neck squamous cell carcinoma, breast and colon cancer (Herman et al., 1995; Merlo et al., 1995). This methylation could lead to lack of expression of CDKN2 protein causing loss of cell cycle control. This will be a subject for further study.

In conclusion, alterations in the CDKN2 gene are infrequent in both primary and metastatic ovarian adenocarcinomas, suggesting that CDKN2 gene mutations play no significant role in the initiation or progression of ovarian cancer. A study on an association with prognosis is not attainable owing to the low prevalence of CDKN2 mutations. Since LOH at 9p21 has been reported in up to

**Figure 2** Sequence analysis of the CDKN2 gene in human ovarian cancer. PCR products with altered migration patterns were analysed. (a and b) Silent mutations in codon 23 (exon 1) and 67 (exon 2). (c) A common polymorphism in codon 148 (exon 2). The asterisks indicate the base changes. Sequences are read from bottom to top in the 5'→3' direction.
50% of primary epithelial ovarian tumours (Chenevix-Trench et al., 1994; Weitzel et al., 1994), one or more other tumour-suppressor genes may be present in the region of 9p21.

Acknowledgements

The authors appreciate the excellent technical assistance of Elly Fuerer. This work was supported by the Dutch Cancer Society (NKB): Grant DDHK 94-840.

References

BERNS EMJ, KLIJN GM, SMIJ M, VAN STAVEREN IL, GRIJS NA AND FOEKENS JA. (1995). Infradent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br. J. Cancer, 72, 964 – 967.

CARNPS, MO, LER, L. LEE DJ, SCWAB D, EBY Y, TONKO K, VAN DER RIET P, BLAURGUND JE AND SIDRANSKY D. (1994). Rates of p16 (MTS1) mutations in primary tumours with 9p loss. Science, 265, 415 – 416.

CARRAS COA, D. COSTA LT, REDSTON MS, SCHUTTE M, SEYMOUR AB, WEINSTEIN CE, HUBRAN RH, YEO CJ AND KERN SE. (1994). Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet., 5, 143 – 149.

CHENG JQ, HJANWAR SC, KLEIN WM, BELL DW, LEE W-C, ALTOMARE DA, NOBEROLOP OLOPA JE, DUCKLER AJ AND TESTA JR. (1994). p16 alterations and deletion mapping of 9p21 – 22 in malignant meseothelioma. Cancer Res., 54, 5547 – 5551.

CHENEVIX-TRENCH, G, KERR J, FRIEDLANDER M, HURST K, SANDERS, S. B. COGLAN M, WARD B, LARTY J AND KOHO SK. (1994). Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors. Am. J. Hum. Genet., 55, 143 – 149.

CHENG JQ, HJANWAR SC, KLEIN WM, BELL DW, LEE W-C, ALTOMARE DA, NOBEROLOP OLOPA JE, DUCKLER AJ AND TESTA JR. (1994). p16 alterations and deletion mapping of 9p21 – 22 in malignant meseothelioma. Cancer Res., 54, 5547 – 5551.

EL-DEIRY WS, TONTKO T, VELCULESCU VE, LEVY DB, PARSONS R, TRENT JM, LIN D, MERCER WE, KINZLIER K AND VOGEL- STEIN B. (1991). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817 – 825.

EL-DEIRY WS, HARRER JW, O’CONNOR PM ET AL. (1994). WAF1/ CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169 – 1175.

GREENAS C, TT MS, BENNETT WP, HOLLSTEN M AND HARRIS CC. (1994). Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855 – 4878.

HARPER JA, ADAMI GR, WEI N, KEYOMARS KI AND ELLEDGE SJ. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805 – 816.

HARTWELL LH AND KASTAN MB. (1994). Cell cycle control and cancer. Science, 262, 1821 – 1828.

HAYASHI K AND YANDELL DW. (1993). How sensitive is PCR – NER? Hum. Mutat., 2, 338 – 346.

HAYASHI N, SUGIYUO T, TSUCHIYA E, OGAWA M AND NAKAMURA Y. (1994). Somatic mutations of the MTS1 (multiple tumor suppressor 1) gene in human primary non-small cell lung carcinoma. Biochem. Biophys. Res. Commun., 202, 1426 – 1430.

HERMAN JM, MELRO A, MAO L, LAPIUS RG, ISSA JP, DAVIDSON NE, SIDRANSKY D AND BAYLIN SB. (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55, 4525 – 4530.

HUNTER T AND PINES J. (1994). Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79, 573 – 582.

HUSSSUSS K, STRUWEING JD, GOLSTEIN AM, HIGGINGS PAT, ALLY DS, SHEEDY ED, CLARK WH, TUCKER MA AND DRACOPOOLI NC. (1994). Germline p16 mutations in familial melanoma. Nature Genet., 5, 15 – 21.

KAMB A, GRIJS NA, WEAVER-FELDHAUS J, LIU Q, HARSHMAN K, TAYRIOAN SY, STOCKERT E, DAVY III RS, JOHNSON BE AND SKOLNICK MH. (1994). A cell cycle checkpoint gene is frequently involved in genesis of many tumor types. Science, 264, 436 – 440.

LYDIATT WM, MURTY VYVS, DAVIDSON B, XU L, DYOMINA K, SACKS PG, SHANTZ HP AND CHAGANTHI RSK. (1993). Homozygous deletion of expression of the CDKN2 gene in cancer. Nature Genet., 5, 94 – 98.